Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
It is unclear whether patients with nondiabetic kidney disease benefit from angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease progression or when they have low urinary protein excretion. With the use of a combined database from 11 randomized, clinical trials (n = 1860), a Cox proportional hazards model, based on known predictors of risk and the composite outcome kidney failure or creatinine doubling, was developed and used to stratify patients into equal-sized quartiles of risk. Outcome risk and treatment effect were examined across various risk strata. Use of this risk model for targeting ACEI therapy was also compared with a strategy based on urinary protein excretion alone. Control patients in the highest quartile of predicted risk had an annualized outcome rate of 28.7%, whereas control patients in the lowest quartile of predicted risk had an annualized outcome rate of 0.4%. Despite the extreme variation in risk, there was no variation in the degree of benefit of ACEI therapy (P = 0.93 for the treatment x risk interaction). Significant interaction was detected between baseline urine protein and ACEI therapy (P = 0.003). When patients were stratified according to their baseline urinary protein excretion, among the subgroup of patients with proteinuria > or =500 mg/d, significant treatment effect was seen across all patients with a measurable outcome risk, including those at relatively low risk (1.7% annualized risk for progression). However, there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d, even among higher risk patients (control outcome rate 19.7%). Patients with nondiabetic kidney disease vary considerably in their risk for disease progression, but the treatment effect of ACEI does not vary across risk strata. Patients with proteinuria <500 mg/d do not seem to benefit, even when at relatively high risk for progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The absence of effect modification by baseline albuminuria contrasts with the findings from trials of RAS blockade.[31][32][33]”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [32]
Citations
Cites
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Self-citation[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00006 · Cited by 1,157
Self-citationAngiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Self-citationPreventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Self-citationRuggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Self-citation
Cited by
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease
Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V., Campo, S., Fazio, M. R., Nicocia, G., & Buemi, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03530708 · Cited by 561
“However, although hypertension, proteinuria, hyperlidemia, and inflammation represent some important modifiable risk factors, by themselves, these elements are not sufficient to properly explain renal outcomes in patients affected by chronic kidney disease (CKD) (1,2).”
Backgroundp-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
Wu, I.-W., Hsu, K.-H., Lee, C.-C., Sun, C.-Y., Hsu, H.-J., Tsai, C.-J., Tzen, C.-Y., Wang, Y.-C., Lin, C.-Y., & Wu, M.-S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq580 · Cited by 510
Kent, D. M., & Hayward, R. A. (2007) · JAMA · doi:10.1001/jama.298.10.1209 · Cited by 505
Self-citationAssessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
“It has been documented that outcome rates in the highest risk quartile (the 25% of study subjects with the highest predicted risk) in large clinical trials is often 5-20 times higher than in the lowest risk quartile [5,16-20].”
BackgroundSelf-citation
Metadata
- Authors
- Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S.
- Affiliations
- Tufts University (US)
- Aga Khan University (PK)
- Michigan Medicine (US)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Copenhagen (DK)
- Corresponding author
- Kent, David M.
- Tighiouart, Hocine
- Landa, Marcia
- Levey, Andrew S.
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-06
- Volume
- 18
- Issue
- 6
- Pages
- 1959-1965
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2155101891
- Semantic Scholar
- 8a3287eeb5c93e1c14342736f701f127afd71ffe
- Cited by
- 162
- References
- 39
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 14 · 2018: 7 · 2017: 5 · 2016: 11 · 2015: 9 · 2014: 12 · 2013: 8 · 2012: 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- non-diabetic kidney disease, ACE inhibitors, disease progression, urinary protein excretion, proteinuria, risk stratification, renal failure, treatment effect heterogeneity
- MeSH terms
- Aged, Algorithms, Angiotensin-Converting Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Proteinuria, Risk Factors, Models, Statistical, Randomized Controlled Trials as Topic, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2006101081
- The paper
- Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007). Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006101081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.